Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Put simply, broccoli fills the stomach
Comparative efficacy across agents semaglutide , dulaglutide , liraglutide , exenatide , lixisenatide , tirzepatide was linked to real-world outcomes, including CVOT findings (REWIND, LEADER, SUSTAIN-6, PIONEER) and FLOW -derived nephroprotection
That does not mean the treatment has failed for one of them
